GS
Gopal Sharan
About Gopal Sharan
Data last updated:
Gopal Sharan is a Director at Ready Cure Lifesciences Private Limited (since 2022). The companies operate in Business Services and Food And Beverages. Ready Cure Lifesciences Private Limited reported revenue of ₹20.8 Lakh (FY 2024). Earlier, Gopal Sharan was a Director at Stanford Biochemical Private Limited (2020–2022).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 06 Mar 2022 | 2018 | ₹20.8 Lakh (FY 2024) | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 29 Jan 2020 | 2020 | Active |
Explore Director's current and past company associations Uncover their professional journey today!
Board colleagues of Gopal Sharan
| Name | DIN | Company | Designation |
|---|---|---|---|
| Maksood Ali | 09526355 | Ready Cure Lifesciences Private Limited | Director |
| Veenas | 11243179 | Ready Cure Lifesciences Private Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Gopal Sharan
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Gopal Sharan
Gopal Sharan currently holds 1 directorship: Ready Cure Lifesciences Private Limited (Director, since 06 Mar 2022, revenue ₹20.8 Lakh (FY 2024)).
Gopal Sharan was first appointed on 29 Jan 2020 as Director at Stanford Biochemical Private Limited. The most recent appointment on record is 06 Mar 2022 at Ready Cure Lifesciences Private Limited.
Gopal Sharan held 1 earlier board appointment: Stanford Biochemical Private Limited (Director, 29 Jan 2020 to 25 May 2022).
The current boards of Gopal Sharan's companies include Maksood Ali (Ready Cure Lifesciences Private Limited), Veenas (Ready Cure Lifesciences Private Limited).